Home > Insider Trading > Filing (0001225208-14-008077)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
810509	Navidea Biopharmaceuticals Inc.	NAVB	In Vitro & In Vivo Diagnostic Substances (2835)	311080091

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1195766	L Brent Larson	5600 Blazer Parkway Suite 200 Dublin OH 43017	Evp, Cfo, Treas & Secy	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-03-10	50,000	$0.49	372,996	No	4	M	Direct
Common Stock	Disposition	2014-03-10	12,312	$1.99	360,684	No	4	F	Direct
Common Stock	Disposition	2014-03-10	41,500	$1.96	319,184	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-03-10	50,000	$0.00	50,000	$0.49

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2014-07-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	93,217	Indirect	By 401(k)

Footnotes

Sales were effected to generate funds required to cover tax obligations arising from expiring options or the vesting of shares of restricted stock. The transaction is matchable under Section 16(b) of the Securities Exchange Act with Mr. Larson's purchase of 5,000 shares of common stock at $1.39 per share on November 8, 2013. As a result, Mr. Larson will pay the company $2,850, representing the full amount of the profit realized in connection with the short-swing transaction.
Option vests 1/3 of the underlying shares annually beginning on the first anniversary of the date of grant.